Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013. https://doi.org/10.1158/1078-0432.CCR-12-3002.
Article
PubMed
Google Scholar
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396–401.
Article
CAS
PubMed
Google Scholar
Cheray M, Begaud G, Deluche E, Nivet A, Battu S, Lalloue F, et al. Cancer stem-like cells in glioblastoma. Brisbane (AU): Codon Publication; 2017.
Book
Google Scholar
Avgeropoulos NG, Batchelor TT. New treatment strategies for malignant gliomas. Oncologist. 1999;4:209–24.
CAS
PubMed
Google Scholar
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.
Article
CAS
PubMed
Google Scholar
Minniti G, Muni R, Lanzetta G, Marchetti P, Enrici RM. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res. 2009;29:5171–84.
CAS
PubMed
Google Scholar
Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 2006;24:2563–9.
Article
CAS
PubMed
Google Scholar
Hart MG, Garside R, Rogers G, Stein K, Grant R. Temozolomide for high grade glioma. Cochrane Database Syst Rev. 2013; 30:CD007415.
Piccirillo SG, Combi R, Cajola L, Patrizi A, Redaelli S, Bentivegna A, Baronchelli S, et al. Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution. Oncogene. 2009;28:1807–11.
Article
CAS
PubMed
Google Scholar
Glas M, Rath BH, Simon M, Reinartz R, Schramme A, Trageser D, et al. Residual tumor cells are unique cellular targets in glioblastoma. Ann Neurol. 2010;68:264–9.
PubMed
PubMed Central
Google Scholar
Piccirillo SG, Dietz S, Madhu B, Griffiths J, Price SJ, Collins VP, Watts C. Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin. Br J Cancer. 2012;107:462–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lama G, Mangiola A, Proietti G, Colabianchi A, Angelucci C, D’ Alessio A, et al. Progenitor/Stem Cell Markers in Brain Adjacent to Glioblastoma: GD3 Ganglioside and NG2 Proteoglycan Expression. J Neuropathol Exp Neurol. 2016;75:134–47.
Article
CAS
PubMed
Google Scholar
Bakshi A, Nag TC, Wadhwa S, Mahapatra AK, Sarkar C. The expression of nitric oxide synthases in human brain tumours and peritumoral areas. J Neurol Sci. 1998;155:196–203.
Article
CAS
PubMed
Google Scholar
Roy S, Sarkar C. Ultrastructural study of micro-blood vessels in human brain tumors and peritumoral tissue. J Neurooncol. 1989;7:283–92.
Article
CAS
PubMed
Google Scholar
Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. The brain tumor microenvironment. Glia. 2012;60:502–14.
Article
PubMed
Google Scholar
Lorger M. Tumor microenvironment in the brain. Cancers. 2012;4:218–43.
Article
PubMed
PubMed Central
Google Scholar
Fazi B, Felsani A, Grassi L, Moles A, D’Andrea D, Toschi N, et al. The transcriptome and miRNome profiling of glioblastoma tissues and peritumoral regions highlights molecular pathways shared by tumors and surrounding areas and reveals differences between short-term and long-term survivors. Oncotarget. 2015;6:22526–52.
Article
PubMed
PubMed Central
Google Scholar
Mangiola A, Saulnier N, De Bonis P, Orteschi D, Sica G, Lama G, et al. Gene expression profile of glioblastoma peritumoral tissue: an ex vivo study. PLoS ONE. 2013;8:e57145.
Article
CAS
PubMed
PubMed Central
Google Scholar
Park I, Tamai G, Lee MC, Chuang CF, Chang SM, Berger MS, et al. Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings. Int J Radiat Oncol Biol Phys. 2007;69:381–9.
Article
PubMed
PubMed Central
Google Scholar
Barciszewska AM, Gurda D, Glodowicz P, Nowak S, Naskret-Barciszewska MZ. A new epigenetic mechanism of temozolomide action in glioma cells. PLoS ONE. 2015;10:e0136669.
Article
CAS
PubMed
PubMed Central
Google Scholar
Alonso MM, Gomez-Manzano C, Bekele BN, Yung WK, Fueyo J. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res. 2007;67:11499–504.
Article
CAS
PubMed
Google Scholar
Nakada M, Furuta T, Hayashi Y, Minamoto T, Hamada J. The strategy for enhancing temozolomide against malignant glioma. Front Oncol. 2012;2:98.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nishikawa R. Standard therapy for glioblastoma-a review of where we are. Neurol Med Chir. 2010;50:713–9.
Article
Google Scholar
Zhao YH, Wang ZF, Cao CJ, Weng H, Xu CS, Li K, et al. The clinical significance of O6-methylguanine-dna methyltransferase promoter methylation status in adult patients with glioblastoma: a meta-analysis. Front Neurol. 2018. https://doi.org/10.3389/fneur.2018.00127.
Article
PubMed
PubMed Central
Google Scholar
Marampon F, Megiorni F, Camero S, Crescioli C, McDowell HP, Sferra R, et al. HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cells. Cancer Lett. 2017;397:1–11.
Article
CAS
PubMed
Google Scholar
Adamopoulou E, Naumann U. HDAC inhibitors and their potential applications to glioblastoma therapy. Oncoimmunology. 2013;2:e25219.
Article
PubMed
PubMed Central
Google Scholar
Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett. 2009;277:8–21.
Article
CAS
PubMed
Google Scholar
Bobustuc GC, Baker CH, Limaye A, Jenkins WD, Pearl G, Avgeropoulos NG, Konduri SD. Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro Oncol. 2010;12:917–27.
Article
CAS
PubMed
PubMed Central
Google Scholar
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20.
Article
PubMed
Google Scholar
Horbinski C, Kofler J, Kelly LM, Murdoch GH, Nikiforova MN. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol. 2009;68:1319–25.
Article
CAS
PubMed
Google Scholar
Caldera V, Mellai M, Annovazzi L, Piazzi A, Lanotte M, Cassoni P, Schiffer D. Antigenic and genotypic similarity between primary glioblastomas and their derived neurospheres. J Oncol. 2011. https://doi.org/10.1155/2011/314962.
Article
PubMed
PubMed Central
Google Scholar
Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, et al. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res. 2008;14:8205–12.
Article
CAS
PubMed
Google Scholar
Binda E, Visioli A, Giani F, Lamorte G, Copetti M, Pitter KL, et al. The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell. 2012;22:765–80.
Article
CAS
PubMed
PubMed Central
Google Scholar
Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008. https://doi.org/10.1007/s00401-008-0455-2.
Article
PubMed
Google Scholar
Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999;59:793–7.
CAS
PubMed
Google Scholar
Zeuner A, Pedini F, Signore M, Testa U, Pelosi E, Peschle C, et al. Stem cell factor protects erythroid precursor cells from chemotherapeutic agents via up-regulation of BCL-2 family proteins. Blood. 2003;102:87–93.
Article
CAS
PubMed
Google Scholar
Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, Wick W. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res. 2008;14:2900–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med. 2005;353:811–22.
Article
CAS
PubMed
Google Scholar
Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia. 2002;39:193–206.
Article
PubMed
Google Scholar
Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821–8.
CAS
PubMed
Google Scholar
Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, Parada LF. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012;488:522–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.
Article
CAS
PubMed
Google Scholar
Burton EC, Prados MD. Malignant gliomas. Curr Treat Options Oncol. 2000;1:459–68.
Article
CAS
PubMed
Google Scholar
Pandith AA, Qasim I, Zahoor W, Shah P, Bhat AR, Sanadhya D, Shah ZA, Naikoo NA. Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide). Sci Rep. 2018;30:6704.
Article
CAS
Google Scholar
Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA, Wu W, James CD, Sarkaria JN. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol. 2009. https://doi.org/10.1215/15228517-2008-090.
Article
PubMed
PubMed Central
Google Scholar
Blough MD, Westgate MR, Beauchamp D, Kelly JJ, Stechishin O, Ramirez AL, Weiss S, Cairncross JG. Sensitivity to temozolomide in brain tumor initiating cells. Neuro Oncol. 2010;12:756–60.
Article
CAS
PubMed
PubMed Central
Google Scholar
van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 2007;6:421–30.
Article
PubMed
Google Scholar
Kim YH, Kim T, Joo JD, Han JH, Kim YJ, Kim IA, Yun CH, Kim CY. Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme. Cancer. 2015. https://doi.org/10.1002/cncr.29439.
Article
PubMed
PubMed Central
Google Scholar
Peddi P, Ajit NE, Burton GV, El-Osta H. Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam. BMJ Case Rep. 2016;23:2016.
Google Scholar